Published in final edited form as:

Acta Neurochir Suppl. 2008 ; 104: 139–147.

Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH

Ryszard M. Pluta

Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

Abstract

Nitric oxide (NO), also known as endothelium-derived relaxing factor, is produced by endothelial nitric oxide synthase (eNOS) in the intima and by neuronal nitric oxide synthase (nNOS) in the adventitia of cerebral vessels. It dilates the arteries in response to shear stress, metabolic demands, pterygopalatine ganglion stimulation and chemoregulation. Subarachnoid hemorrhage (SAH) interrupts this regulation of cerebral blood flow. Hemoglobin, gradually released from erythrocytes in the subarachnoid space, destroys nNOS-containing neurons in the conductive arteries. This deprives the arteries of NO, leading to initiation of delayed vasospasm. But such vessel narrowing increases shear stress, which stimulates eNOS. This mechanism normally would lead to increased production of NO and dilation of arteries. However, a transient eNOS dysfunction evoked by an increase in the endogenous competitive NOS inhibitor, asymmetric dimethylarginine (ADMA), prevents this vasodilation. eNOS dysfunction has been recently shown to be evoked by increased levels of ADMA in cerebrospinal fluid (CSF) in response to the presence of bilirubin-oxidized fragments (BOXes). A direct cause of the increased ADMA CSF level is most likely decreased ADMA elimination owing to disappearance of ADMA-hydrolyzing enzyme [dimethylarginine dimethylaminohydrolase II (DDAH II)] immunoreactivity in the arteries in spasm. This eNOS dysfunction sustains vasospasm. CSF ADMA levels are closely associated with the degree and time course of vasospasm; when CSF ADMA levels decrease, vasospasm resolves. Thus, exogenous delivery of NO, inhibiting the L-arginine-methylating enzyme or stimulating DDAH II, may provide new therapeutic modalities to prevent and treat vasospasm. This paper will present results of pre-clinical studies supporting the NO-based hypothesis of delayed cerebral vasospasm development and its prevention by increased NO availability.

Keywords

Nitric oxide; NO donors; SAH; vasospasm; PDE; ADMA; nitrite

INTRODUCTION

Annually, as many as 28,000 Americans suffer subarachnoid hemorrhage (SAH) from a ruptured intracranial aneurysm. About 1 week after the SAH, a severe narrowing of the cerebral arteries develops in up to 70% of them^{42,86,92,107} and results in delayed ischemic neurological deficits (DIND) in ~25% of these patients. Half of the post-SAH patients suffer severe permanent neurological dysfunction or death owing to DIND^{42,86,92}. Despite intensive worldwide research, and the fact that the first report of DIND was published in the mid-19th century²⁶ and that cerebral vasospasm was diagnosed for the first time more than 50 years ago¹⁸, its pathomechanism remains unclear⁷⁰.

In spite of some controversies, hemoglobin has been accepted as a cause of vasospasm^{53,54}. Since the discovery that nitric oxide (NO), an endothelium-derived relaxing factor²², has 1000 times higher affinity for hemoglobin than oxygen⁵², neurosurgeons and neuroscientists have been interested in its role in cerebral vasospasm after SAH^{2,8,16,44,45,55,64–66,70,87,90,92,94,95,103}. NO influence on blood flow^{11,15,99,106,113}, disappearance of neuronal nitric oxide synthase (nNOS) immunoreactivity from the arteries in spasm⁷⁵, endothelial nitric oxide synthase (eNOS) dysfunction in cerebral vessels after SAH³⁷, decreased levels of nitrite in the cerebrospinal fluid (CSF) during vasospasm development^{40,70,76}, as well NO affinity for the heme moiety⁵² together, strongly suggest that decreased availability of NO in the cerebral arterial wall after SAH is responsible for delayed cerebral vasospasm⁷⁰. Recent research has significantly advanced our understanding of the NO-related pathophysiologic changes in the cerebral arteries leading to vasospasm and introduced new possibilities for NO-based therapy for vasospasm^{23,76,98}.

NO AND PATHOMECHANISM(S) OF DELAYED CEREBRAL VASOSPASM

There is little doubt that ferrous hemoglobins (oxyhemoglobin and deoxyhemoglobin) slowly released from erythrocytes in the subarachnoid space oxidized and metabolized are directly and/or indirectly responsible for development of cerebral vasospasm^{13,54,71} (*Figure 1*). At the time of vasospasm, the nNOS-expressing (nitroxic nNOS-containing) neurons disappear from the arterial adventitia⁷⁵, diminishing NO availability and resulting in vasoconstriction⁷⁰ (*Figure 1*). However, this initial narrowing of the artery stimulates eNOS by increased shear stress³⁵. Thus, increased NO production should counteract decreased NO availability and lead to vasodilation. But the persistence of delayed cerebral vasospasm, lowered cyclic guanosine monophosphate (cGMP) levels in the arterial wall⁴³ and decreased nitrites in the CSF^{39,70,73,76} (*Figure 1*) with preserved expression of eNOS⁷⁵ suggest the existence of an endothelial dysfunction that affects eNOS and decreases NO production³⁷. This eNOS dysfunction may result from increased activity of phosphodiesterase (PDE) leading to quicker elimination of 3',5'-cGMP⁹⁰ or as recently has been shown, it may be evoked by endogenous inhibition of eNOS by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS³⁹ (*Figure 1*), probably in response to the presence of oxidized degradation fragments of bilirubin (BOXes) in hemorrhagic CSF¹³. Recently, the presence of ADMA (Jung *et al.*, in preparation) and BOXes in the CSF and their association with the degree and time course of vasospasm have been reported in patients with SAH^{13,78}. This mechanism sustains vasospasm. Then in the last phase of vasospasm, oxidation and

elimination of BOXes reduce ADMA levels in the CSF³⁹ (Jung *et al.*, in preparation), resulting in increased NO production by eNOS and recovery of endothelial dilatory activity⁷⁰.

Decreased nitrite levels and their close correlation with development and degree of vasospasm after SAH^{39,70,73,76} (Figure 1) further support the hypothesis that decreased NO availability is responsible for or at least significantly contributes to cerebral vasospasm⁷⁰. Reversal and prevention of cerebral vasospasm by NO/NO donors support this hypothesis^{2,72}.

Thus, decreased NO availability in the cerebral conductive arteries responsible for development of vasospasm is evoked by the initial elimination of nNOS (the first hit) by oxyhemoglobin followed by inhibition of eNOS by ADMA in the perivascular space (the second hit).

These observations suggest that the NO-based mechanism of delayed cerebral vasospasm remains not only multifactorial or affecting different structures of the arterial wall but also longitudinal (i.e. dependent on the time-related change in hemoglobin released from the subarachnoid clot)⁷⁰ and as such should be addressed accordingly.

NO-BASED PREVENTION AND TREATMENT OF VASOSPASM

Incomplete understanding of the etiology of vasospasm has hindered the development of successful treatment^{53,109,110}. Although the pathogenesis of vasospasm after SAH is probably multifactorial, imbalance between vasoconstricting (endothelin-1, endothelium-derived constricting factor) and vasodilating influences on vascular tone in response to the presence of blood in the subarachnoid space almost certainly play an integrating role^{54,71}. The above mentioned mechanisms of initiation, sustenance and resolution of delayed cerebral vasospasm open the possibility to develop vasospasm-preventing treatment with NO replacement and sequential, targeted therapy, which may yield a novel treatment for this life-threatening complication of SAH.

nNOS protection

The initial treatment directly after SAH was proposed many years ago^{20,27} and fortunately was recently rediscovered⁴⁷. It is to remove the clot and bloody CSF thereby decreasing levels of neurotoxic oxyhemoglobin in the vicinity of conductive vessels. Recombinant tissue plasminogen activator (rt-PA) was used to enhance the effect of CSF drainage²⁰. The removal of blood and its degradation products from the vicinity of the cerebral arteries should prevent death of noxious neurons in the adventitia of the arteries and block initial spasm of the arteries as well as decrease the availability of oxyhemoglobin that can be metabolized to BOXes. However, it is unlikely that all the blood can be removed. Because in this phase of vasospasm, the dominant effect that has to be blocked is oxyhemoglobin neurotoxicity, chelation of ferrous iron of oxyhemoglobin by an intracellular Fe²⁺ iron chelator such as dipyrindyl has been proposed³³. Eliminating ferrous hemoglobin by either or both of these methods may prevent neuronal apoptosis in the adventitia protecting a basic mechanism of the neuronal vasodilatory response^{75,101}. Another beneficial effect of both

these therapies may be to reduce oxidative stress in the subarachnoid space and in the vicinity of the conductive arteries that should then decrease the levels of vasoactive heme metabolites, especially BOXes¹³. This should successfully block deactivation of dimethylarginine dimethylaminohydrolase (DDAH) thus limiting ADMA increase in the CSF and dysfunction of eNOS.

NO delivery: systemic

During the initial phase of vasospasm, NO replacement may be a helpful adjunct because it should quench oxyhemoglobin as has been proposed by Doyle¹⁷ leading to its oxidation (methemoglobin) and/or nitrosylation/nitration [S-nitroso (SNO)-hemoglobin Fe(II)HbNO]. This NO-based quenching effect on ferrous hemoglobins ('the reversed sink effect') should enhance the effectiveness of CSF drainage and iron chelation resulting in further protection of nNOS and eNOS activities.

In the past, NO was administered systemically in the form of nitrates as nitroglycerin (NTG) and sodium nitroprusside [S-nitroso-N-acetylpenicillamine (SNAP)]^{21,31,45}. Intravenous delivery of NTG/SNAP was efficacious in preventing cerebral vasospasm in animal models^{19,36,60}. However, using NTG/SNAP in animals and patients was limited by its strong hypotensive effect^{19,45}. Therefore, it was proposed that NTG/SNAP be combined with hyper-tensive agents³. Furthermore, a non-discriminative dilation of the cerebral vasculature led to development of the 'steal syndrome'^{4,36,68}, increased intracranial pressure (ICP)¹⁹ and lower perfusion pressure. Thus, this technique of NO delivery did not spark clinical interest because of the high risk of potential ischemic complications (especially in hemodynamically unstable patients with cerebral vasospasm) and the difficulty of predicting pharmacokinetics because nitrates require an enzymatic step to release NO^{5,29,93}.

Recently, small-dose nitroglycerin delivery via a transdermal patch was shown to prevent cerebral vasospasm in a rabbit model of SAH avoiding the undesirable decrease in blood pressure³⁶. But its effectiveness needs to be confirmed clinically. Furthermore, the long-term therapy (2–3 weeks) with SNAP resulted in cyanide toxicity⁸⁰. We have also tried intravenous delivery of a newly developed NO donor⁸², which spontaneously releases NO and has an extremely short half life (1.8 seconds). However, we saw no effect on delayed cerebral vasospasm before decreased arterial blood pressure was observed (Pluta, unpublished data).

Despite yielding positive results in experimental settings and in some preliminary pilot clinical studies, nitrates as NO donors had limited effectiveness because of their significant vasodilatory peripheral effect, which led to decreased blood pressure (with a possible disastrous decrease in cerebral blood flow or cyanide toxicity). However, all these obstacles can be overcome by the systemic use of nitrite.

Nitrite, on demand, local but systemically administered NO donor

Recently, it has been reported that in blood, nitrite is an endogenous NO donor^{14,108} indicating a major bioavailable pool of NO with deoxyhemoglobin acting as a nitrite reductase during hypoxic conditions in acidic environment^{10,14,59}. Similar conditions (i.e. presence of deoxyhemoglobin⁷¹ and low pH⁸³) exist in the subarachnoid space after SAH.

Therefore, the lower CSF nitrite levels after SAH and during development of vasospasm may be caused not only by decreased NO production by neuronal and endothelial NOS, but also by increased consumption of nitrite. Therefore, intravenous delivery of nitrite should overcome diminished NO production in the arterial wall after SAH.

Nitrite has unique properties as an endogenous NO donor. Under physiologic pH, nitrite forms nitrous acid, which can react with nitrite to form N_2O_3 ²⁵. These reactive nitrogen species can nitrosate thiols (which can also be vasoactive) or in the presence of an electron donor, produce NO^{14,25}. Recently, this mechanism was confirmed both *in vitro*⁵⁹ and *in vivo*^{14,76,108} showing that deoxyhemoglobin and presumably other deoxyheme proteins reduce nitrite to NO. We tested the hypothesis that nitrite releases NO locally in the subarachnoid space in a primate model of SAH⁷⁶ and demonstrated that intravenous continuous infusion of sodium nitrite for 14 days prevents development of vasospasm without effect on blood pressure and with only clinically insignificant increases in methemoglobin levels in blood.

Despite these good safety records and the fact that nitrite has been used in the meat, poultry and fish industries because of its antibacterial action especially against botulinum spores⁸⁹ for centuries, there are potential problems with its use. A Food and Drug Administration (FDA)-supported study reported that nitrite doubles the risk of lymphomas in rat⁶² and suggested that it increased cancer incidence and tumor growth rate in animal studies⁹¹. Nevertheless, the human studies did not clarify this issue. Some of them confirmed the association between nitrite in food and development of neoplasms especially in the brain³⁴, others were inconclusive⁵⁷ and some completely rejected the association, at least in adults in Eastern Nebraska¹². Furthermore, one study has shown that inhalant nitrite increased angiogenesis resulting in accelerated tumor growth¹⁰², while another demonstrated that the increased nitrite levels correlated positively with vasculo- and angiogenesis²⁴. But the opposite effect was also reported, showing that NO inhibited angiogenesis and tumor growth⁶⁹. These controversial and unclear results³⁴, the fact that nitrite is still used in the meat industry⁸⁹ and the recently reported presence of nitrite and nitrosamines in many organs including brain, aorta, liver, kidney and the heart¹⁰ suggest that nitrite may not be as dangerous as previously thought and that carefully designed epidemiologic studies of nitrite's biologic role are necessary. Also, additional well-planned studies of dosing and adverse effects of sodium nitrite should elucidate the pharmacokinetics of sodium nitrite in humans, establish the proper dosage and safety profile and hopefully offer a new therapeutic modality for patients surviving aneurysmal SAH.

NO delivery: regional

Isolation of brain vasculature for regional drug delivery was developed many decades ago with the first cerebral arteriography performed by E. Moniz in 1935⁵⁸. Development of cerebral arteriography followed by a non-selective opening of the blood–brain barrier with intracarotid infusion of mannitol for chemotherapy⁶¹ and development of endovascular treatment for vascular central nervous system (CNS) diseases by Serbinienko⁸⁸ have proven the therapeutic possibility of isolating the brain vasculature using endovascular access. They were further followed by intra-arterial angioplasty and delivery of papaverine against

vasospasm^{41,51}, as well as intra-arterial administration of rt-PA to treat thrombotic stroke^{9,84}. Thus, to avoid the peripheral vasodilatory effect of systemic NO donor administration, two changes have been made: route of administration was changed to direct intracarotid/intracerebral arteries infusion^{2,41,51,74} and nitrates were replaced by non-enzymatic NO donors. These donors included: NO gas solution², 3-morpholiniosydnonimine, SNAP, S-nitrosoglutathione¹¹¹, diazeniumdiolates (NONOates)^{74,82} and recently nitrite⁷⁶. Among all NO donors, NONOates have received the most attentions: NONOates owing to release of NO with predictable pharmacokinetics (half life ranging from a second to several hours). ProliNO with a $T_{1/2}$ =1.7 seconds was an obvious favorite to study NO effect on cerebral vasculature^{72,74,108}. However, because of the obvious disadvantages of intracarotid/intracerebral arterial drug administration that include increased risk of severe complications, patient and family anxiety and necessity of around-the-clock accessibility of the neurointerventional team, this treatment was not clinically attractive.

NO delivery: local

Traditionally, local delivery indicates that a drug is administered directly in the vicinity of a targeted area. Until recently, with regard to NO delivery, this indicates that NO gas, NO donor or nitrate had to be delivered to the affected organ, the lung (inhalation) or topically on the surface of the exposed tissue, etc.

In the case of aneurysmal SAH, local administration is delivering NO donors intrathecally or intraventricularly^{19,79,97,98,112}. Such a route can avoid many disadvantages of systemic administration. However, drug distribution delivered intrathecally in the SAH setting is poorly understood. It is difficult to accept that any compound delivered intrathecally and/or intraventricularly with the thick clot enveloping the conductive arteries in the subarachnoid space can penetrate the clot to reach the arterial wall to exert its effect directly on this artery. Moreover, intrathecal and/or intraventricular delivery of a strong vasodilator can cause vessels that are more easily accessible (i.e. those that are not covered by the clot) to further dilate, resulting in the 'steal syndrome'^{4,68}. None of these issues has been properly addressed either experimentally or clinically and both a beneficial effect^{19,97,98,112} and failure to improve cerebral vasospasm were reported with NO donors administrated via these routes⁷⁹.

It appears that all of the above mentioned drawbacks of NO delivery can be avoided by the newly proposed delivery of the NO donor directly into the vicinity of the artery by placing a controlled-release polymer loaded with the NO donor at the time the aneurysm is surgically repaired. This method was reported to prevent vasospasm with the NO donor and ibuprofen in a primate model of SAH but needs a further clinical confirmation^{23,77}. The obvious disadvantage of this method is that it requires surgical access to the region of interest and with the rapidly increasing popularity of endovascular therapy^{28,63} instead of surgical treatment for intracranial aneurysm, its use may be limited.

Another NO addressing therapies for cerebral vasospasm

Inhibition of ADMA production—NO production is tightly controlled by multilevel mechanisms requiring the presence of oxygen and L-arginine as substrates for enzymatic

cleavage of NO by NOS, the enzyme, which for proper action requires the presence of several coenzymes [heme, flavin adenine mono- and dinucleotides, nicotinamide adenine dinucleotide phosphate (NADPH) and tetrahydrobiopterin] as well as cofactors (calcium and calmodulin)⁷. Furthermore, NOS activity is modulated by an 'internal' negative feedback between NO and a heme moiety of NOS³⁵, as well as by competitive inhibition of NOS by ADMA produced by double methylation of L-arginine by a type I protein-arginine methyl transferase (PRMT I) and degraded by DDAH¹⁰⁴.

We have shown that in a primate model of SAH and in patients following a ruptured aneurysm, ADMA CSF levels significantly increased concurrently with the development of vasospasm and gradually decreased with vasospasm resolution³⁹ (Jung *et al.*, in preparation). The degree of arteriographic vasospasm and the concentration of ADMA in the CSF were tightly correlated and CSF ADMA levels followed the time course of vasospasm³⁹ (Jung *et al.*, in preparation). These results suggest that endogenous inhibition of NOS by ADMA may be a source of endothelial dysfunction facilitating and supporting development of cerebral vasospasm following SAH especially since DDAH2 activity disappears from the arteries in spasm after SAH³⁹.

The regulation of PRMT and DDAH activities has been recently carefully studied. It has been reported that the second end product of NOS activity, L-citrulline, inhibits DDAH¹⁰⁴ and that S-nitrosylation of DDAH also inhibited its action⁵⁰. Moreover, it has been shown that low-density lipoprotein (LDL) cholesterol up-regulates ADMA synthesis by activation of PRMT⁶ suggesting that statins, drugs lowering plasma cholesterol levels, may at least indirectly affect DDAH activity. Statins are known to correct endothelial dysfunction^{30,85} and recently Simvastatin was shown to increase eNOS activity and ameliorate vasospasm⁵⁶. Yet another cholesterol-lowering drug, probucol, was shown to promote functional re-endothelization of stripped aorta⁴⁸ and to preserve endothelial vasodilatory functions by reducing ADMA levels³⁸. Thus, we used probucol, a drug with high octanol/water partition coefficient ($\log P=10.91$)⁸⁵ assuring significant penetration of the blood-brain barrier, to inhibit increased ADMA levels in CSF after SAH and prevent development of vasospasm in a primate model of SAH⁷³.

In the *in vitro* experiments, probucol confirmed³⁸ its potency to decrease ADMA production by endothelial cells. *in vitro*, it also increased nitrite levels, suggesting that it stimulated NO production⁴⁹ by eNOS^{46,96,114} in response to increased DDAH activity¹.

These results encouraged the pre-clinical trial of probucol in a double-blinded, placebo-controlled experiment to investigate its effectiveness to inhibit increased ADMA levels in CSF and to prevent vasospasm. Unfortunately, probucol administered orally, despite achieving therapeutic levels in serum, failed to inhibit ADMA increases in CSF or prevent vasospasm after SAH.

Despite the clear failure of probucol, the results of this study do not exclude the possibility that pharmacologically lowering CSF ADMA levels by a proper agent¹ may prevent development of post-hemorrhagic delayed cerebral vasospasm. At this moment, at least two more drugs are of interest because they were shown to increase DDAH activity. Both

estrogen³² and all-trans-retinoic acid stimulated DDAH activity leading to increased NO production by eNOS¹.

Prevention of vasospasm by PDE selective inhibitor—NO relaxes smooth muscle cells and dilates blood vessels stimulating soluble guanylate cyclase, which produces 3',5'-cGMP. The latter sequesters intracellular Ca²⁺, which relaxes vascular smooth muscles. Intracellular cGMP is inactivated by cyclic nucleotide PDEs. There are several isoforms of PDEs (types 1–6); however, only PDE5 is abundant in vascular smooth muscle cells. PDE5 inhibitors (such as Viagra) have been used to increase blood flow and dilate blood vessels. However, their use is limited owing to their non-selective activity. Recently, a group of highly selective intracellular PDE5 inhibitors (E4021 and SCH 51866) were introduced in clinical trials to control hypertension, pulmonary hypertension, respiratory distress, platelet aggregation and erectile dysfunction^{67,100,105}. Thus, there is a possibility that increased 3',5'-cGMP in the cerebral arterial wall by selective inhibition of PDE5 can prevent development of delayed vasospasm after SAH. Nevertheless, to elucidate the role of cGMP and PDE5 inhibitor in development of delayed vasospasm, well-designed experimental and clinical studies need to be carried out.

CONCLUSION

Despite significant progress on the pathophysiology of delayed cerebral vasospasm following ruptured intracranial aneurysm, there is no treatment for this dreadful complication of SAH. However, recent advancements in understanding the roles of NO, NO donors, NOS and nitrite in physiologic and pathophysiologic conditions, suggest the possible development of a therapy which will address decreased NO availability in cerebral arteries, thereby avoiding the undesirable side effects of nitrates.

ACKNOWLEDGEMENT

This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke.

REFERENCES

1. Achan V, Tran C, Arrigoni F, et al. All-trans-retinoic acid increases nitric oxide synthesis by endothelial cells. A role for the induction of dimethylarginine dimethylaminohydrolase. *Circ Res.* 2002; 90:764–769. [PubMed: 11964368]
2. Afshar J, Pluta RM, Boock RJ, et al. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. *J Neurosurg.* 1995; 83:118–122. [PubMed: 7782826]
3. Allen GS. Cerebral arterial spasm. Part 8: The treatment of delayed cerebral arterial spasm in human beings. *Surg Neurol.* 1976; 6:71–80. [PubMed: 951655]
4. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: A holistic view of its actions. *Crit Rev Neurosurg.* 1999; 9:303–318. [PubMed: 10525849]
5. Blaumanis, OR.; Grady, PA.; Nelson, E. Hemodynamic and morphologic aspects of cerebral vasospasm.. In: Price, TR.; Nelson, E., editors. *Cerebrovascular Diseases*. Raven Press; New York: 1979. p. 283-294.
6. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. *Circ Res.* 2000; 87:99–105. [PubMed: 10903992]

7. Bredt D, Hwang P, Glatt C, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. *Nature*. 1991; 351:714–718. [PubMed: 1712077]
8. Brown FD, Hanlon K, Crockard HA, et al. Effect of sodium nitroprusside on cerebral blood flow in conscious human beings. *Surg Neurol*. 1977; 7:67–70. [PubMed: 835075]
9. Brown MM. Brain attack: A new approach to stroke. *Clin Med*. 2002; 2:60–65.
10. Bryan NS, Rassaf T, Maloney RE, et al. Cellular targets and mechanisms of nitros(yl)ation: An insight into their nature and kinetics in vivo. *Proc Natl Acad Sci USA*. 2004; 101:4308–4313. [PubMed: 15014175]
11. Buchanan JE, Philis JW. The role of nitric oxide in the regulation of cerebral blood flow. *Brain Res*. 1993; 610:248–255. [PubMed: 8319087]
12. Chen H, Ward MH, Tucker KL, et al. Diet and risk of adult glioma in eastern Nebraska, United States. *Cancer Causes Control*. 2002; 13:647–655. [PubMed: 12296512]
13. Clark JF, Reilly M, Sharp FR. Oxidation of bilirubin produces compounds that cause prolonged vasospasm of rat cerebral vessels: A contributor to subarachnoid hemorrhage-induced vasospasm. *J Cereb Blood Flow Metab*. 2002; 22:472–478. [PubMed: 11919518]
14. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. *Nat Med*. 2003; 9:1498–1505. [PubMed: 14595407]
15. Dirnagl U, Lindauer U, Villringer A. Role of nitric oxide coupling of cerebral blood flow to neuronal activation in rats. *Neurosci Lett*. 1992; 149:43–46. [PubMed: 8469377]
16. Dorsch NW. Therapeutic approaches to vasospasm in subarachnoid hemorrhage. *Curr Opin Crit Care*. 2002; 8:128–133. [PubMed: 12386513]
17. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. *J Inorg Biochem*. 1981; 14:351–358. [PubMed: 7276933]
18. Ecker A, Rimenschneider PA. Arteriographic demonstration of spasm of the intracranial arteries with special reference to saccular arterial aneurysms. *J Neurosurg*. 1951; 8:660–667. [PubMed: 14889314]
19. Egemen N, Turker RK, Sanlidilik U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. *Neurol Res*. 1993; 15:310–315. [PubMed: 7905604]
20. Findlay JM, Weir BK, Steinke D, et al. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in primate model of SAH. *J Neurosurg*. 1988; 69:723–735. [PubMed: 3141595]
21. Frazee JG, Giannotta SL, Stern WE. Intravenous nitroglycerin for the treatment of chronic cerebral vasoconstriction in the primate. *J Neurosurg*. 1981; 55:865–868. [PubMed: 6795315]
22. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980; 288:373–376. [PubMed: 6253831]
23. Gabikian P, Clatterbuck RE, Eberhart CG, et al. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: Toxicity and efficacy studies in rabbits and rats. *Stroke*. 2002; 33:2681–2686. [PubMed: 12411661]
24. Gallo O, Masino E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. *J Natl Cancer Inst*. 1998; 90:587–596. [PubMed: 9554441]
25. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: Role in blood flow regulation. *Free Rad Biol Med*. 2004; 36:707–716. [PubMed: 14990351]
26. Gull WM. Cases of aneurism of the cerebral vessels. *Guys Hosp Rep*. 1859; 5:281–304.
27. Handa Y, Weir BK, Nosko M, et al. The effect of timing of clot removal on chronic vasospasm in a primate model. *J Neurosurg*. 1987; 67:558–564. [PubMed: 3655894]
28. Hanel RA, Lopes DK, Wehman JC, et al. Endovascular treatment of intracranial aneurysms and vasospasm after aneurysmal subarachnoid hemorrhage. *Neurosurg Clin N Am*. 2005; 16:317–353. [PubMed: 15694165]
29. Hashi K, Mayer JS, Shinmaru S, et al. Cerebral hemodynamic and metabolic changes after experimental subarachnoid hemorrhage. *J Neurol Sci*. 1972; 17:1–14. [PubMed: 4626886]
30. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of

- endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. *J Clin Invest*. 1998; 101:2711–2719. [PubMed: 9637705]
31. Heros RC, Zervas NT, Lavyne MH, et al. Reversal of experimental cerebral vasospasm by intravenous nitroprusside therapy. *Surg Neurol*. 1976; 6:227–229. [PubMed: 968722]
 32. Holden DP, Cartwright JE, Nussey SS, et al. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. *Circulation*. 2003; 108:1575–1580. [PubMed: 12963642]
 33. Horky LL, Pluta RM, Boock RJ, et al. Ferrous iron chelator 2,2'-dipyridyl prevents delayed vasospasm in a primate model of subarachnoid hemorrhage. *J Neurosurg*. 1998; 88:298–303. [PubMed: 9452239]
 34. Huncharek M, Kupelnick B. A meta-analysis of maternal cured meat consumption during pregnancy and the risk of childhood brain tumors. *Neuroepidemiology*. 2004; 23:78–84. [PubMed: 14739572]
 35. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: A historical overview. *J Physiol Pharmacol*. 2002; 53:503–514. [PubMed: 12512688]
 36. Ito Y, Isotani E, Mizuno Y, et al. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. *J Cardiovasc Pharmacol*. 2000; 35:45–50. [PubMed: 10630732]
 37. Iuliano BA, Pluta RM, Jung C, et al. Endothelial dysfunction in a primate model of cerebral vasospasm. *J Neurosurg*. 2004; 100:287–294. [PubMed: 15086237]
 38. Jiang JL, Li NS, Li YJ. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. *Br J Pharmacol*. 2002; 135:1175–1182. [PubMed: 11877324]
 39. Jung CS, Iuliano BA, Harvey-White J, et al. Association between cerebrospinal fluid levels of asymmetric dimethyl-L-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage. *J Neurosurg*. 2004; 101:836–842. [PubMed: 15543672]
 40. Jung, CS.; Iuliano, BA.; Harvey-White, J., et al. CSF levels of ADMA, an endogenous inhibitor of nitric oxide synthase, are associated with cerebral vasospasm after subarachnoid hemorrhage.. In: Macdonald, R., editor. *Cerebral Vasospasm: Proceedings of the 8th International Conference*. Thieme; New York: 2004. p. 92-93.
 41. Kassell NF, Helm G, Simmons N, et al. Treatment of cerebral vasospasm with intra-arterial papaverine. *J Neurosurg*. 1992; 77:848–852. [PubMed: 1432125]
 42. Kassell NF, Torner JC. The International Cooperative Study in timing of aneurysm surgery—an update. *Stroke*. 1984; 15:566–570. [PubMed: 6729890]
 43. Kasuya H, Weir BK, Nakane M, et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar artery after subarachnoid hemorrhage. *J Neurosurg*. 1995; 82:250–255. [PubMed: 7529302]
 44. Kiris T, Karasu A, Yavuz C, et al. Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. *Acta Neurochir (Wien)*. 1999; 141:1323–1328. [PubMed: 10672304]
 45. Kistler JP, Lees RS, Candia G, et al. Intravenous nitroglycerin in experimental cerebral vasospasm. A preliminary report. *Stroke*. 1979; 10:26–29. [PubMed: 107621]
 46. Kleinbongard P, Dejam A, Lauer T, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. *Free Rad Biol Med*. 2003; 35:790–796. [PubMed: 14583343]
 47. Klimo P Jr, Kestle JR, MacDonald JD, et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. *J Neurosurg*. 2004; 100:215–224. [PubMed: 15086227]
 48. Lau AK, Leichtweis SB, Hume P, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. *Circulation*. 2003; 107:2031–2036. [PubMed: 12681995]
 49. Lauer T, Preik M, Rassaf T, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. *Proc Natl Acad Sci USA*. 2001; 98:12814–12819. [PubMed: 11606734]
 50. Leiper J, Murray-Rust J, McDonald N, et al. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide

synthase and dimethylarginine dimethylaminohydrolase. *Proc Natl Acad Sci USA*. 2002; 99:13527–13532. [PubMed: 12370443]

51. Little N, Morgan MK, Grinnell V, et al. Intra-arterial papaverine in the management of cerebral vasospasm following subarachnoid hemorrhage. *J Clin Neurosci*. 1994; 1:42–46. [PubMed: 18638725]
52. Liu X, Miller MJ, Joshi MS, et al. Diffusion-limited reaction of free nitric oxide with erythrocytes. *J Biol Chem*. 1998; 273:18709–18713. [PubMed: 9668042]
53. Macdonald, R.; Weir, B., editors. *Cerebral Vasospasm*. Academic Press; San Diego, CA: 2001. p. 449–450.
54. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. *Stroke*. 1991; 22:971–982. [PubMed: 1866764]
55. Macdonald RL, Zhang ZD, Curry D, et al. Intracisternal sodium nitroprusside fails to prevent vasospasm in nonhuman primates. *Neurosurgery*. 2002; 51:761–770. [PubMed: 12188956]
56. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. *Stroke*. 2002; 33:2950–2956. [PubMed: 12468796]
57. McKean-Cowdin R, Pogoda JM, Lijinsky W, et al. Maternal prenatal exposure to nitrosatable drugs and childhood brain tumours. *Int J Epidemiol*. 2003; 32:211–217. [PubMed: 12714539]
58. Moniz E. [Scientific raisins from 125 years SMW (Swiss Medical Weekly). Clinical and physiological results of cerebral angiography. 1935]. *Schweiz Med Wochenschr*. 1995; 125:1503–1507. [PubMed: 7676240]
59. Nagababu E, Ramasamy S, Abernethy DR, et al. Active nitric oxide produced in the red cell under hypoxic conditions by deoxyhemoglobin-mediated nitrite reduction. *J Biol Chem*. 2003; 278:46349–46356. [PubMed: 12952953]
60. Nakao K, Murata H, Kanamaru K, et al. Effects of nitroglycerin on vasospasm and cyclic nucleotides in a primate model of subarachnoid hemorrhage. *Stroke*. 1996; 27:1882–1887. [PubMed: 8841348]
61. Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood–brain barrier modification and combination chemotherapy: Concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. *Neurosurgery*. 1984; 15:362–366. [PubMed: 6090973]
62. Newberne PM. Nitrite promotes lymphoma incidence in rats. *Science*. 1979; 204:1079–1081. [PubMed: 451551]
63. Newell DW, Eskridge J, Mayberg M, et al. Endovascular treatment of intracranial aneurysms and cerebral vasospasm. *Clin Neurosurg*. 1992; 39:348–360. [PubMed: 1458749]
64. Ng WH, Moomchala S, Yeo TT, et al. Nitric oxide and subarachnoid hemorrhage: Elevated levels in cerebrospinal fluid and their implications. *Neurosurgery*. 2001; 49:622–627. [PubMed: 11523672]
65. Nishizawa S, Yamamoto S, Yokoyama T, et al. Dysfunction of nitric oxide synthase induces protein kinase C activation resulting in vasospasm after subarachnoid hemorrhage. *Neurol Res*. 1997; 19:558–562. [PubMed: 9329037]
66. Ohkita M, Takaoka M, Shiota Y, et al. Nitric oxide inhibits endothelin-1 production through the suppression of nuclear factor kappa B. *Clin Sci (London)*. 2002; 103(Suppl. 48):S68–S71.
67. Oka M. Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries. *Am J Physiol Lung Cell Mol Physiol*. 2001; 280:L432–L435. [PubMed: 11159025]
68. Paulson OB. Regional cerebral blood flow in apoplexy due to occlusion of the middle cerebral artery. *Neurology*. 1970; 20:63–77. [PubMed: 5460771]
69. Pipili-Synetos E, Papageorgious A, Sakkoula E, et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. *Br J Pharmacol*. 1995; 116:1829–1834. [PubMed: 8528567]
70. Pluta RM. Delayed cerebral vasospasm and nitric oxide: Review, new hypothesis, and proposed treatment. *Pharmacol Ther*. 2005; 105:23–56. [PubMed: 15626454]

71. Pluta RM, Afshar JK, Boock RJ, et al. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin and, methemoglobin after subarachnoid hemorrhage. *J Neurosurg.* 1998; 88:557–561. [PubMed: 9488312]
72. Pluta, RM.; Boock, RJ.; Oldfield, E. Intracarotid chronic infusion of nitric oxide donors prevents cerebral vasospasm in a primate model of subarachnoid hemorrhage.. Present at American Association of Neurological Surgeons Annual Meeting; Denver, CO, USA. 1997.
73. Pluta RM, Jung CS, Shilad S, et al. Probucol does not inhibit production of ADMA or prevent vasospasm in randomized, double-blind placebo-controlled trial in a primate model of vasospasm. *J Neurosurg.* 2005; 103:731–738. [PubMed: 16266057]
74. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. *J Neurosurg.* 1997; 87:746–751. [PubMed: 9347984]
75. Pluta RM, Thompson BG, Dawson TM, et al. Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. *J Neurosurg.* 1996; 84:648–654. [PubMed: 8613858]
76. Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to prevent delayed cerebral artery vasospasm in a primate model of subarachnoid aneurismal hemorrhage. *JAMA.* 2005; 293:1477–1484. [PubMed: 15784871]
77. Pradilla G, Thai QA, Legnani FG, et al. Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. *Neurosurgery.* 2004; 55:1393–1399. [PubMed: 15574221]
78. Pyne-Geithman GJ, Morgan CJ, Wagner K, et al. Bilirubin production and oxidation in CSF of patients with cerebral vasospasm after subarachnoid hemorrhage. *J Cereb Blood Flow Metab.* 2005; 25:1070–1077. [PubMed: 15789034]
79. Raabe A, Zimmermann M, Setzer M, et al. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. *Neurosurgery.* 2002; 50:1006–1013. [PubMed: 11950403]
80. Ram Z, Spiegelman R, Findler G, et al. Delayed postoperative neurological deterioration from prolonged sodium nitroprusside administration. Case report. *J Neurosurg.* 1989; 71:605–607. [PubMed: 2795179]
81. Reid; Johnson; Ollenshow. 6th International Congress of Radiology, London, Cited after White, R. Experimental findings in intracranial aneurysm. In: Fox, JL., editor. *Vasospasm. Vol. I.* Springer-Verlag; New York: 1950. p. 218-249.
82. Saavedra JE, Southan GJ, Davies KM, et al. Localizing anti-thrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor. *J Med Chem.* 1996; 39:4361–4365. [PubMed: 8893830]
83. Sambrook MA, Hutchinson EC, Aber GM. Metabolic studies in subarachnoid haemorrhage and strokes. I. Serial changes in acid-base values in blood and cerebrospinal fluid. *Brain.* 1973; 96:171–190. [PubMed: 4695721]
84. Saver JL. Intra-arterial thrombolysis. *Neurology.* 2001; 57(Suppl. 2):S58–S60. [PubMed: 11552057]
85. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). *J Am Coll Cardiol.* 2002; 39:610–616. [PubMed: 11849859]
86. Schievink WI. Intracranial aneurysms. *N Engl J Med.* 1997; 336:28–40. [PubMed: 8970938]
87. Sehba FA, Cheresnev I, Maayani S, et al. Nitric oxide synthase in acute alteration of nitric oxide levels after subarachnoid hemorrhage. *Neurosurgery.* 2004; 55:671–677. [PubMed: 15335435]
88. Serbinenko FA. Six hundred endovascular neurosurgical procedures in vascular pathology. A ten-year experience. *Acta Neurochir Suppl (Wien).* 1979; 28:310–311. [PubMed: 290181]
89. Smith RJ. Nitrites: FDA beats a surprising retreat. *Science.* 1980; 209:1100–1101. [PubMed: 7403871]
90. Sobey CG. Cerebrovascular dysfunction after subarachnoid haemorrhage: Novel mechanisms and directions for therapy. *Clin Exp Pharmacol Physiol.* 2001; 28:926–929. [PubMed: 11703398]
91. Soderberg LS. Increased tumor growth in mice exposed to inhaled isobutyl nitrite. *Toxicol Lett.* 1999; 104:35–41. [PubMed: 10048747]

92. Stapf, C.; Mohr, JP. Aneurysms and subarachnoid hemorrhage-epidemiology.. In: LeRoux, PD.; Winn, HR.; Newell, DW., editors. Management of Cerebral Aneurysms. WB Saunders; Philadelphia, PA: 2004. p. 183-187.
93. Steinmeier R, Laumer R, Bondar I, et al. Cerebral hemodynamics in subarachnoid hemorrhage evaluated by Transcranial Doppler sonography. Part 2. Pulsatility Indices: Normal reference values and characteristics in subarachnoid hemorrhage. Neurosurgery. 1993; 33:10–19. [PubMed: 8355825]
94. Stoodley M, Macdonald RL, Weir B, et al. Subarachnoid hemorrhage as a cause of an adaptive response in cerebral vessels. J Neurosurg. 2000; 93:463–470. [PubMed: 10969945]
95. Stoodley M, Weihl CC, Zhang ZD, et al. Effect of adenovirus-mediated nitric oxide synthase gene transfer on vasospasm after experimental subarachnoid hemorrhage. Neurosurgery. 2000; 46:1193–1202. [PubMed: 10807252]
96. Suzuki Y, Osuka K, Noda A, et al. Nitric oxide metabolites in the cisternal cerebral spinal fluid of patients with subarachnoid hemorrhage. Neurosurgery. 1997; 41:807–812. [PubMed: 9316041]
97. Thomas JE, Nemirovsky A, Zelman V, et al. Rapid reversal of endothelin-1-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurgery. 1997; 40:1245–1249. [PubMed: 9179898]
98. Thomas JE, Rosenwasser RH. Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: Initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery. 1999; 44:48–57. [PubMed: 9894963]
99. Thompson BG, Pluta RM, Gorton ME, et al. Nitric oxide mediation of chemoregulation but not autoregulation of cerebral blood flow in primates. J Neurosurg. 1996; 84:71–78. [PubMed: 8613839]
100. Thompson WJ, Piazza GA, Li H, et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000; 60:3338–3342. [PubMed: 10910034]
101. Toda N, Tanaka T, Ayajiki K, et al. Cerebral vasodilatation induced by stimulation of the pterygopalatine ganglion and greater petrosal nerve in anesthetized monkeys. Neuroscience. 2000; 96:393–398. [PubMed: 10683579]
102. Tran DC, Yeh KC, Brazeau DA, et al. Inhalant nitrite exposure alters mouse hepatic angiogenic gene expression. Biochem Biophys Res Commun. 2003; 310:439–445. [PubMed: 14521929]
103. Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: A problem of neurointensive care. Neurosurgery. 2001; 48:249–261. [PubMed: 11220367]
104. Vallance P, Chan N. Endothelial function and nitric oxide: Clinical relevance. Heart. 2001; 85:342–350. [PubMed: 11179281]
105. Vemulapalli S, Watkins RW, Chintala M, et al. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996; 28:862–869. [PubMed: 8961086]
106. Watkins LD. Nitric oxide and cerebral blood flow: An update. Cerebrovasc Brain Metab Rev. 1995; 7:324–337. [PubMed: 8703673]
107. Weir B, Grace M, Hansen J, et al. Time course of vasospasm in man. J Neurosurg. 1978; 48:173–181. [PubMed: 624965]
108. Weyerbrock A, Walbridge S, Pluta RM, et al. Selective opening of the blood–tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. J Neurosurg. 2003; 99:728–737. [PubMed: 14567609]
109. Wilkins RH. Attempted prevention or treatment of intracranial arterial spasm: A survey. Neurosurgery. 1980; 6:198–210. [PubMed: 6767999]
110. Wilkins RH. Attempts at prevention or treatment of intracranial arterial spasm: An update. Neurosurgery. 1986; 18:808–825. [PubMed: 3526171]
111. Wink DA, Cook JA, Pacelli R, et al. Effect of various nitric oxide-donor agents on hydrogen peroxide mediated toxicity: A direct correlation between nitric oxide formation and protection. Arch Biochem Biophys. 1996; 331:241–248. [PubMed: 8660704]

112. Wolf EW, Banerjee A, Soble-Smith J, et al. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor. *J Neurosurg.* 1998; 89:279–288. [PubMed: 9688124]
113. Zhang F, White JG, Iadecola C. Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: Evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. *J Cereb Blood Flow Metab.* 1994; 14:217–226. [PubMed: 8113318]
114. Zweier JL, Wang P, Samouilov A, et al. Enzyme-independent formation of nitric oxide in biological tissues. *Nat Med.* 1995; 1:804–809. [PubMed: 7585184]

Figure 1.

Hypothesis of three NO-related phases of development of delayed cerebral vasospasm.

Initially, ferrous hemoglobins (oxyHb and deoxyhemoglobin) released from erythrocytes scavenge NO (decreased levels of nitrite in CSF) and oxyHb destroys nNOS-containing neurons in the cerebral arteries (disappearance of nNOS activity from the arteries in spasm, lower picture of the first panel of histologic slides) (**Phase I**). Then, ferrous hemoglobins are oxidized to methemoglobin and metabolized to bilirubin-biliverdin by heme oxygenase up-regulated after SAH. In the presence of oxidative stress, bilirubin/biliverdin produces bilirubin oxidation products (BOXes). Then, BOXes via purported inhibition of dimethylarginine dimethylamine hydrolase (DDAH), the enzyme responsible for asymmetric dimethylarginine (ADMA) hydrolysis, increases ADMA levels and inhibits eNOS (**Phase II**), leading to prolongation of vasospasm (center panel of histologic slides). Then, via still unknown mechanism, ADMA levels decrease, probably owing to elimination of BOXes and reactivation of DDAH, and delayed cerebral vasospasm resolves (**Phase III**).

Adapted from *Pharmacology and Therapeutics*, 2005; **105**: 23–56, with permission from Elsevier

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript